Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Extended Half-Life Products Cut Infusions in Europe

Key clinical point: Preliminary data suggest novel extended half-life factor VIII (FVIII) and factor IX (FIX) products maintain higher trough levels and decrease the number of infusions in patients with hemophilia.

Major finding: Across 33 hemophilia treatment centers, extended half-life FVIII products decreased the number of infusions by 30% or greater and achieved trough levels of 3%-5% in 66%-67% of centers, respectively.

Study details: A European multinational survey of 33 hemophilia treatment centers.

Disclosures: No funding sources were reported. The authors reported financial affiliations with Alnylam, Grifols, Kedrion, Pfizer, Roche, Sanofi, Bayer, Shire, and several other companies.


Peyvandi F et al. Haemophilia. 2019 Aug 16. doi: 10.1111/hae.13834.